Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Fat Loss and Metabolism

LIRAGLUTIDE

An FDA-approved GLP-1, but unlike the weekly ones, it’s a daily injection (brands Saxenda for weight, Victoza for diabetes). Shorter-acting, so it has to be dosed every day.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

An FDA-approved GLP-1, but unlike the weekly ones, it’s a daily injection (brands Saxenda for weight, Victoza for diabetes).

Shorter-acting, so it has to be dosed every day.

What It Does

Liraglutide is a GLP-1 receptor agonist with a ~13-hour half-life, requiring once-daily dosing.

It enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.

FDA-approved as Victoza (diabetes, up to 1.8 mg) and Saxenda (weight, up to 3.0 mg).

Reconstitution

Vial SizeBAC Water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
30 mg+ 6 mL5 mg/mL
Phase (1 wk each)FrequencyDose
Week 1Daily0.6 mg
Week 2Daily1.2 mg
Week 3Daily1.8 mg
Week 4Daily2.4 mg
Week 5+Daily3.0 mg
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

PROTOCOL (SAXENDA WEIGHT-LOSS TITRATION)

Phase (1 wk each)FrequencyDoseUnits (5 mg/mL)Notes
Week 1Daily0.6 mg12uDaily dosing, not weekly. Same time each day.
Week 2Daily1.2 mg24u
Week 3Daily1.8 mg36uVictoza (diabetes) max is 1.8 mg.
Week 4Daily2.4 mg48u
Week 5+Daily3.0 mg60uSaxenda weight-loss maintenance. Cycle: weekly 0.6 mg steps to the 3.0 mg maintenance; continuous daily use for the indication. Timing: once daily, same time, independent of meals. Note: daily dosing means high vial use vs weekly GLP-1s, budget accordingly. Women: Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises testosterone, SHBG and gonadotropins as weight drops, improves sperm and erectile function, and preserves fertility (unlike TRT).

Handling & Stacking

Injection site
SubQ, abdomen/thigh/upper arm. Rotate daily.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within 28 days.
  • No clear reconstituted-potency data (the pen label gives an in-use date, not potency), so defer to the 28-day sterility limit. (Commercial pens are pre-filled, refrigerated.)
Side effects
Nausea, diarrhea, constipation, vomiting, headache, reduced appetite. GI effects dose-dependent, usually early.
What to expect
  • Appetite suppression and glucose lowering within weeks; weight loss over months (moderate, generally less than weekly semaglutide).
  • Supply math 30mg → 9 vials | 10mg → 26 vials (12-wk @ 3 mg/day, daily dosing is vial-heavy)
Pairs well with
Lipo-C / L-Carnitine (metabolic support). Do not combine with other GLP-1 / incretin agents
Avoid
Personal/family history of medullary thyroid carcinoma or MEN2. Prior pancreatitis. Pregnancy. Other GLP-1s

Safety & Patient Education

Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2 (boxed warning) Prior pancreatitis Pregnancy and lactation Type 1 diabetes / diabetic ketoacidosis
Warnings
Thyroid C-cell tumors in rodents (boxed warning) Gallbladder disease with rapid weight loss Hypoglycemia when combined with insulin/sulfonylureas Acute kidney injury from dehydration Heart-rate increase
Drug interactions
Insulin / sulfonylureas: reduce dose to avoid hypoglycemia Delayed gastric emptying alters oral drug absorption Other GLP-1 agents: do not combine
Labs
  • Fasting glucose / HbA1c (baseline + periodic) Renal function with significant GI losses Lipase if pancreatitis suspected Resting heart rate (GLP-1s nudge it up a few bpm; the label says to check it) Out of range?
  • Rising glucose/HbA1c = creeping toward diabetes (recheck, tighten diet); falling eGFR = kidney strain, usually dehydration (hydrate, hold).
Stop criteria
Severe persistent abdominal pain (pancreatitis) Persistent vomiting / dehydration Signs of gallbladder disease Pregnancy
Patient education
This one is daily, missing days blunts results, unlike weekly GLP-1s
H d t
d i t i t i i t k